Interestingly, C/EBPβ was shown to protect ovarian cancers against cisplatin treatment by enforcing the expression of genes involved in drug transport, cell survival, and DNA repair, more precisely homologous recombination repair and non-homologous end-joining (61). This evidence concerns the gene CEBPB and ovarian carcinoma.